FANCF and ovarian carcinoma: This finding was subsequently confirmed by Wang et al (2006), who found methylation in 5 out of 18 cases of ovarian cancer, but no study has formally addressed the issue of whether loss of FANCF function, via methylation-dependent silencing, influences clinical outcome in patients treated with cisplatin.